TXG
10x Genomics, Inc.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$62.65
−0.90%Year over year
Reported trailing growth
- Revenue
- -4.3%
- EBITDA
- +172.7%
- EBIT
- +12.1%
- EPS
- +15.7%
- Free cash flow
- +113.5%
- Operating cash flow
- +89.8%
Forward estimates
Based on analyst estimates
- Revenue
- +4.7%
- EBITDA
- —
- EPS
- -32.6%
Three-year CAGR
- Revenue
- +7.6%
- EBITDA
- +102.9%
- EBIT
- +43.0%
- Net income
- +76.2%
- EPS
- +77.0%
- Free cash flow
- +2371.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026